Search Results 361-370 of 16158 for first%20aide%20basic

  1. Hematology - Clinical trials

    Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma. Rochester, Minn., La Crosse, Wis., Mankato ...

  2. Stroke - Doctors and departments - Mayo Clinic

    Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to ...

  3. Stroke - Doctors and departments - Mayo Clinic

    Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to ...

  4. Stroke - Doctors and departments - Mayo Clinic

    Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to ...

  5. Stroke - Doctors and departments - Mayo Clinic

    Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to ...

  6. Mayo Clinic Precure – Prospective Study

    ... early and effective interventions, and develop biologically targeted therapies. Participation eligibility. Participant eligibility includes age, gender, type ...

  7. A Study To Evaluate ARV-806 In Adults With Advanced Cancer That Has The KRAS G12D Mutation - Mayo Clinic

    This will be the first time ARV-806 will be used in people. The investigational drug will be given through a vein. This is called intravenous (IV) infusion ...

  8. Stroke - Doctors and departments - Mayo Clinic

    Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to ...

  9. Hematology - Clinical trials

    Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma. Rochester, Minn., La Crosse, Wis., Mankato ...

  10. A Study to Compare CMP-001 Combined with Nivolumab to Nivolumab Alone in Advanced Melanoma Subjects - Mayo Clinic

    The primary objective of Phase 3 is to evaluate progression-free survival (PFS) for subjects receiving first-line CMP-001 in combination with nivolumab versus ...